Skip to main content
Caplight Logo









Adel, Inc.

Adel, Inc.

Private
SeoulHealthcare & Life Scienceshttps://adelpharm.com/

Last Round

Private Equity

Apr 9, 2026

Est. Valuation

$277.5M

Total Funding Raised

$56.02M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Adel, Inc. is a biopharmaceutical company that develops therapeutic antibodies and diagnostic systems for neurodegenerative diseases, with a primary focus on Alzheimer's disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

Alzheimer's treatmentmonoclonal antibodymAbtau protein targetingneurodegenerative diseasedrug licensingdrug discoverydisease-modifying treatmentimmunotherapyclinical stage biotechbiopharmaADTAC platformbrain targetingautophagy targetingsmall moleculetau-based diagnosticApoE4 targeting

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Adel, Inc. Comparables

Compare Adel, Inc. with similar companies based on industry and business-model similarity.

Adel, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Oscotec Inc
83%
Amyloid Solution Inc.
79%
Prothena Corporation plc
78%

Adel, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Private EquityApr 9, 2026
Series B ExtensionJul 31, 2024
Series BOct 1, 2020

Key People

Founding team and executive leadership

Youngsoo Sohn

COO

Executive Team

Adel, Inc. Investors

Notable investors and investment history

Adel, Inc. investors
InvestorRounds
Smilegate InvestmentSeries B Extension, Private Equity
Korea Investment PartnersPrivate Equity
Samsung SecuritiesPrivate Equity
DS Asset ManagementPrivate Equity
Mirae Asset SecuritiesPrivate Equity
Timefolio Asset ManagementPrivate Equity
Samsung Venture InvestmentPrivate Equity

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 37% MoM, reaching 11.2K.

  • Apr 27, 2026

    Grew 50% QoQ, from 6 to 9 employees.

Adel, Inc. Filings

Explore SEC and related filing metadata, where available.

Adel, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Adel, Inc.'s valuation, stock price, and market status.

Is Adel, Inc. a public or private company?

Adel, Inc. is a private company.

What is the current stock price of Adel, Inc.?

Adel, Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is Adel, Inc. worth (valuation)?

Valuation information for Adel, Inc. is not publicly available.

Can I buy Adel, Inc. stock?

Adel, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Adel, Inc.'s last funding round?

Funding round information for Adel, Inc. is not publicly available.

Who are the main investors in Adel, Inc.?

Investor information for Adel, Inc. is not publicly disclosed.

Will Adel, Inc. IPO soon?

No public IPO plans have been announced for Adel, Inc..

How can I track Adel, Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Adel, Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSeoul
Employee Range11
Year Founded2016
Last FundingApr 9, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?